The global prevalence of<unk>  is approximately 10 million people. In most populations studied, heterozygous<unk>  occurs in about 1:250 people, but not all develop symptoms. Homozygous<unk>  occurs in about 1:1,000,000. LDLR mutations are more common in certain populations, presumably because of a genetic phenomenon known as the founder effect—they were founded by a small group of individuals, one or several of whom was a carrier of the mutation. The Afrikaner, French Canadians, Lebanese Christians, and Finns have high rates of specific mutations that make<unk>  particularly common in these groups. APOB mutations are more common in Central Europe.
Familial hypercholesterolemia
Familial hypertriglyceridemia
Combined hyperlipidemia
Apolipoprotein B deficiency
Familial multiple lipomatosis
Marfanoid
Fruitarianism
Fabry disease